<unk>  is indicated for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Ciltacabtagene autoleucel
Brexucabtagene autoleucel
Lisocabtagene maraleucel
Idecabtagene vicleucel
Ibrexafungerp
Levomilnacipran
Nicogel
Brodifacoum